Unlike insulin or other non discretionary drugs, there is a wide gap between the eligible population and the number of people actually on therapy
Low-dose GLP treatments are being trialed for some chronic inflammatory conditions such as MCAS (mast cell activation syndrome)
[1] [2] Persistent gastrointestinal symptoms can lead to reduced nutritional intake, dehydration, and electrolyte disturbances, all of which may present as fatigue
And our current thinking is that if someone's developing obesity, particularly moderate to severe obesity in this society, they most likely have a genetic predisposition from our ancestors to put on calories and they don't balance their body fat very well
A key structural feature is the incorporation of an alpha-aminoisobutyric acid (Aib) at several positions to enhance proteolytic stability against dipeptidyl peptidase-4 (DPP-4)
Those with a history of pancreatitis or thyroid cancer Individuals using the drug solely for vanity weight loss without medical need Pregnant or breastfeeding women Ultimately, consultation with a licensed medical provider is essential
